Join
Live feed
·
INSIDERFilingvia Quantisnow
Recursion Pharmaceuticals Inc. logo

Director Borgeson Blake sold $105,600 worth of shares (30,000 units at $3.52) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,199,863 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RXRX· Recursion Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RXRX (Recursion Pharmaceuticals Inc.) and more on Quantisnow.